Nureca Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited reported annual revenue from operations of ₹1,472.10 million for FY26, up 28.4% from ₹1,146.40 million in FY25, crossing the 20% revenue growth threshold. The company turned profitable with PAT of ₹2.97 million versus a loss of ₹6.68 million in the previous year. However, Q4 FY26 alone showed a significant loss of ₹66.25 million. Statutory auditors issued an unmodified (clean) opinion on the financial results. The Board approved ₹100 crore incremental capex for manufacturing medical devices and healthcare products at its Punjab facility, along with land purchase for future expansion. Key management changes include CFO Mr. Naresh Gupta's resignation and appointment of Mr. Chander Kant as new CFO. The company completed a share buyback at ₹330 per share during the year, reducing share capital from ₹100 million to ₹95.42 million. Related party disclosures show three Goyal family members (Aryan, Saurabh, and Smita) holding 45.87% combined equity shares.
Revenue growth is positive, but the Q4 loss raises concerns about profitability sustainability. The ₹100 crore capex approval signals expansion intent but will require capital deployment. Share buyback and management transitions are neutral-to-moderately negative due to CFO resignation timing.